

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



百信集團
PASHUN GROUP

Pa Shun Pharmaceutical International Holdings Limited

百信藥業國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 574)

PROPOSED CHANGE OF COMPANY NAME

The Board announces that a special resolution will be proposed at the AGM for the Shareholders to consider and, if thought fit, approve the change of the English name of the Company from “Pa Shun Pharmaceutical International Holdings Limited” to “Pa Shun International Holdings Limited” and the dual foreign name in Chinese of the Company from “百信藥業國際控股有限公司” to “百信國際控股有限公司”.

A circular containing, among other things, information in relation to the Change of Company Name and a notice convening the AGM will be despatched to the Shareholders as soon as practicable.

PROPOSED CHANGE OF COMPANY NAME

The board (“**Board**”) of directors (“**Directors**”) of Pa Shun Pharmaceutical International Holdings Limited (“**Company**”, together with its subsidiaries, the “**Group**”) proposes to change the English name of the Company from “Pa Shun Pharmaceutical International Holdings Limited” to “Pa Shun International Holdings Limited” and the dual foreign name in Chinese of the Company from “百信藥業國際控股有限公司” to “百信國際控股有限公司” (“**Change of Company Name**”).

CONDITIONS OF THE CHANGE OF COMPANY NAME

The proposed Change of Company Name will be subject to the following conditions:

- (1) the passing of a special resolution by the shareholders of the Company (“**Shareholders**”) at the forthcoming annual general meeting of the Company (“**AGM**”) to approve the Change of Company Name; and
- (2) the Registrar of Companies of the Cayman Islands granting the approval for the Change of Company Name by issuing a certificate of incorporation on change of name.

Subject to the satisfaction of the conditions set out above, the Change of Company Name will take effect from the date of the certificate of incorporation on change of name issued by the Registrar of Companies of the Cayman Islands. The Company will then carry out the necessary filing procedures with the Companies Registry in Hong Kong.

REASONS FOR THE CHANGE OF COMPANY NAME

Taking into account that the pharmaceutical industry in China is highly competitive, in addition to implementing the current strategies for its pharmaceutical business segments, the Group also intends to make good use of its existing resources and networks to seize the opportunity of extending to other areas of innovation for development.

The Board considers that the Change of Company Name could better reflect the future business development direction of the Group and strengthen the Group’s corporate image and identity. The Board believes that the Change of Company Name is in the best interests of the Company and the Shareholders as a whole.

EFFECT OF THE CHANGE OF COMPANY NAME

The Change of Company Name will not affect any rights of the holders of securities of the Company. The existing certificates of securities in issue bearing the present name of the Company will, after the Change of Company Name becoming effective, continue to be evidence of title to such securities and the existing certificates of securities will continue to be valid for trading, settlement, registration and delivery purposes. There will not be any arrangement for exchange of the existing certificates of securities for new certificates bearing the new name of the Company. Should the Change of Company Name become effective, any new certificates of securities will be issued only in the new name of the Company.

Further announcement(s) will be made by the Company in due course to inform the Shareholders of the results of the AGM, the effective date of the Change of Company Name and the new stock short name of the Company for trading of the shares of the Company on The Stock Exchange of Hong Kong Limited.

GENERAL

The AGM will be convened and a special resolution will be proposed thereat for the Shareholders to consider and, if thought fit, approve the Change of Company Name. A circular containing, among other things, information in relation to the Change of Company Name and a notice convening the AGM will be despatched to the Shareholders as soon as practicable.

On behalf of the Board

Pa Shun Pharmaceutical International Holdings Limited

Mr. Chen Yenfei

Chairman and Chief Executive Officer

Hong Kong, 5 April 2017

As at the date of this announcement, the executive Directors are Mr. Chen Yenfei, Mr. Shen Shun, Mr. Zhou Jian; the non-executive Director is Mr. Li Ho Tan, Mr. Zhang Xiongfeng and Mr. Masahiro Honna; and the independent non-executive Directors are Mr. Liu Liangzhong, Mr. Wong Tak Shing and Mr. Min Feng.